Received Jul 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | M4B34 | — |
Twinrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 53-year-old female patient who received HAB (Twinrix) (batch number M4B34, expiry date 28-SEP-2026) for prophylaxis. Previously administered products included Twinrix (received 1st dose on 19-NOV-2024 with batch number 2553X and lot expiry 25-SEP-2026). On 08-JUL-2025, the patient received the 2nd dose of Twinrix. On 08-JUL-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Twinrix late second dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 09-JUL-2025 The pharmacist asked what was the recommended time interval between dose two and three of Twinrix taking into account that the second dose was given late, which led to drug dose administration interval too long. The vaccine administration facility was the same as primary reporter.